Explore more publications!
Tech Journal of Colorado
Submit Press Release

Tech Journal of Colorado: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 29, 2025

Space Force Association Welcomes Five New Corporate Members: Collins Aerospace, DiSTI, K2 Space, Bluestaq, and Novawurks
September 29, 2025

Space Force Association Welcomes Five New Corporate Members: Collins Aerospace, DiSTI, K2 Space, Bluestaq, and Novawurks

Indeterminate EIN Presswire
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Indeterminate GlobeNewswire
Artelo Biosciences Announces Proposed Underwritten Public Offering
September 29, 2025

Artelo Biosciences Announces Proposed Underwritten Public Offering

Indeterminate GlobeNewswire
Ramsey Theory Group CEO Dan Herbatschek Unveils Ethical AI Roadmap to Drive Transformation — Without Sacrificing Human Jobs
September 29, 2025

Ramsey Theory Group CEO Dan Herbatschek Unveils Ethical AI Roadmap to Drive Transformation — Without Sacrificing Human Jobs

Indeterminate GlobeNewswire
Altai Announces Sale of Cessford Oil Wells Property
September 29, 2025

Altai Announces Sale of Cessford Oil Wells Property

Indeterminate GlobeNewswire
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
September 29, 2025

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Indeterminate GlobeNewswire
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …
September 29, 2025

NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …

Indeterminate GlobeNewswire
Voxtur Announces Purchase of Secured Indebtedness by Hale Capital Partners
September 29, 2025

Voxtur Announces Purchase of Secured Indebtedness by Hale Capital Partners

Indeterminate GlobeNewswire
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025

INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Indeterminate GlobeNewswire
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
September 29, 2025

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Indeterminate GlobeNewswire
Viomi Celebrates 7th Nasdaq Anniversary with New Brand Campaign and U.S. Launch of AI Alkaline Mineral Water Purifier, MASTER M1
September 29, 2025

Viomi Celebrates 7th Nasdaq Anniversary with New Brand Campaign and U.S. Launch of AI Alkaline Mineral Water Purifier, MASTER M1

Indeterminate GlobeNewswire
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
September 29, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Indeterminate GlobeNewswire
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
September 29, 2025

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Indeterminate GlobeNewswire
MAIA Biotechnology Announces $2.25 Million Private Placement
September 29, 2025

MAIA Biotechnology Announces $2.25 Million Private Placement

Indeterminate GlobeNewswire
IDT Corporation Reports Fourth Quarter and Fiscal Year 2025 Results
September 29, 2025

IDT Corporation Reports Fourth Quarter and Fiscal Year 2025 Results

Indeterminate GlobeNewswire
American Rebel Holdings, Inc. (NASDAQ: AREB) and TSR Nitro Celebrate the American Rebel Beer Dodge Hellcat Victory at NHRA Midwest Nationals—Matt Hagan Wins Big in St. Louis
September 29, 2025

American Rebel Holdings, Inc. (NASDAQ: AREB) and TSR Nitro Celebrate the American Rebel Beer Dodge Hellcat Victory at NHRA Midwest Nationals—Matt Hagan Wins Big in St. Louis

Indeterminate GlobeNewswire
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 29, 2025

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Indeterminate GlobeNewswire
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
September 29, 2025

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Indeterminate GlobeNewswire
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Indeterminate GlobeNewswire
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
September 29, 2025

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions